[{"orgOrder":0,"company":"Cordis","sponsor":"MedAlliance","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cordis","amount2":1.1399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1399999999999999,"dosageForm":"","sponsorNew":"Cordis \/ Cordis","highestDevelopmentStatusID":"12","companyTruncated":"Cordis \/ Cordis"}]

Find Clinical Drug Pipeline Developments & Deals by Cordis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.

                          Brand Name : Selution SLR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 18, 2022

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Recipient : MedAlliance

                          Deal Size : $1,135.0 million

                          Deal Type : Acquisition

                          blank